ONEVIEW HEALTHCARE PLC (ONE)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ONE

ONE - ONEVIEW HEALTHCARE PLC

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.11
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.17

30 Apr
2026

0.000

OPEN

$0.17

0.000

HIGH

$0.17

84,374

LOW

$0.16

TARGET
$0.45 164.7% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
ONE: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) - 1.7 xxx
DPS (cps) N/A xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in EUR.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-2.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx21.0 M
Book Value Per Share xxxxxxxxxxxxxxx0.8
Net Operating Cash Flow xxxxxxxxxxxxxxx-14.6 M
Net Profit Margin xxxxxxxxxxxxxxx-104.89 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-154.18 %
Return on Invested Capital xxxxxxxxxxxxxxx-139.31 %
Return on Assets xxxxxxxxxxxxxxx-62.34 %
Return on Equity xxxxxxxxxxxxxxx-154.18 %
Return on Total Capital xxxxxxxxxxxxxxx-119.22 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-14.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx8 M
Price To Book Value xxxxxxxxxxxxxxx47.25

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.2 M
Capex % of Sales xxxxxxxxxxxxxxx0.97 %
Cost of Goods Sold xxxxxxxxxxxxxxx8 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx32 M
Research & Development xxxxxxxxxxxxxxx20 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

28/04/2026

1

Speculative Buy

$0.45

164.71%

Oneview Healthcare announced March quarter cash receipts of around EUR3.3m, a fall of -22.9% y/y which Bell Potter attributes to timing issues around receipts compared to the previous year.

Lower operating costs flowed through due to business restructuring in 2025 while net operating cash flow came in flat at around EUR1.3m.

The company had a cash balance of EUR10.3m versus EUR4.6m in the previous quarter from the recent placement.

This offers eight quarters of funding for operations, Bell Potter observes.

Speculative Buy rating and 45c target unchanged. EPS forecasts remain unchanged with the broker assuming around 20% growth annually in live endpoints from FY26-FY28.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.74 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.04 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

ONE STOCK CHART

FNArena News on ONE

4
ASX Companies Adopt ESG Global Reporting Tool

Jun 01 2021 - FYI
5
Telehealth: Part Of Healthcare Revolution

May 12 2021 - Australia

Latest Medical Equipment & Devices News

1
Shortages Chip Away At ResMed’s Big Break

Mar 30 2022 - Australia
2
Opportunity for Fisher & Paykel Healthcare

Mar 25 2022 - Australia
3
Distribution Anxiety For Nanosonics

Feb 10 2022 - Australia
4
Brokers Awake To ResMed’s Potential

Jan 31 2022 - Australia
5
Covid Benefits F&P Healthcare, For Now

Dec 06 2021 - Australia
6
Will Shortages Limit Upside For ResMed?

Nov 01 2021 - Australia
7
Nanosonics Unveils Its New Product

Aug 26 2021 - Australia
8
Pro Medicus: Opportunity Awaits

Aug 24 2021 - Technicals
9
Breakout For Cochlear

Aug 10 2021 - Technicals
10
Will ResMed’s Market Share Gains Last?

Aug 09 2021 - Australia